Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1

Status

Completed 48Unknown 17Recruiting 13Terminated 11Active not recruiting 6Withdrawn 3Not yet recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 1NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 1Neuroblastoma 1Neoplasms 1Leukemia, Myeloid, Acute 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Cyclophosphamide 128Cisplatin 119Radiotherapy 111pembrolizumab 110Paclitaxel 96Gemcitabine 96Carboplatin 96Nivolumab 76Magnetic Resonance Spectroscopy 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Doxorubicin 52fludarabine 51Biopsy 48durvalumab 44Cytarabine 44Drug Therapy 43Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Lenalidomide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Interventional × Tretinoin × Clear all
NCT01048086 2016-06-21

90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)

University of Iowa

Phase 2 Withdrawn
CNSEndocrineNET

Neuroblastoma, Neuroendocrine Tumors

NCT01067274 2015-12-30

ALFA-0703

Acute Leukemia French Association

Phase 3 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01349556 2014-04-23

Prevention of Drug Rash From Certain Cancer Therapies Using Tretinoin Cream

Johns Hopkins University

Phase NA Withdrawn

Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡